German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck has been in pursuit of eligible candidates that could ... Japan's Daiichi Sankyo to jointly develop three of its ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Gdansk: German science and technology group Merck is open to more acquisitions for its Life Science business after announcing ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

We recently published a list of 10 Most Promising Low-Cost Stocks According to Hedge Funds. In this article, we are going to ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...